ClinicalTrials.gg
CompletedNCT00147199TRIUMPHUpdated Jan 2, 2024Results posted

Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)

A Phase 3 interventional study of Inhaled treprostinil and Placebo inhalation solution in Pulmonary Hypertension, sponsored by United Therapeutics. Completed at 30 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-02.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's title name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
235
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
6th of 44
235 · median 32
Started
2005
with 2 others
Phase 3
14 of 44
1 open now
Registered
2nd of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 6th largest by enrollment, is one of 3 that started in 2005, is one of 14 in phase 3, and was the 2nd registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This is a double-blind placebo-controlled clinical investigation into the efficacy and tolerability of inhaled treprostinil in patients with severe pulmonary arterial hypertension. The primary outcome is the change in 6-minute walk distance from baseline to week 12.

Read the detailed description

Patients who have been on a stable dose of 125 mg twice daily (bid) of bosentan or any stable dose of sildenafil for at least three months prior to study start were randomized to either treprostinil inhalation solution or matching placebo.

Administration of study medication was performed by inhalation with the OPTINEB™ ultrasonic nebulizer.

The proposed dosing regimen was four times daily-upon awakening, at midday, evening (dinner time) and bedtime.

After a patient has completed the twelve-week study period, they were given the option of enrolling into an open-label extension study.

03

Conditions studied

  • Pulmonary Hypertension

Browse trials for

Keywords

  • Pulmonary Arterial Hypertension
04

In context

Pulmonary Arterial Hypertension Reclassified

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.

This study's enrollment of 235 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically stable, pulmonary arterial hypertension diagnosed as either idiopathic or familial PAH, collagen vascular disease associated PAH, PAH, or PAH induced by anorexigens, (NYHA) Class III or Class IV.
  • Been on a stable dose of 125 mg twice daily (bid) of bosentan OR any stable dose of sildenafil for at least three months prior to study start
  • An unencouraged six minute walk test (6MWT) of between 200 and 450 meters at screening
  • Cardiac catheterization within the past 13 months consistent with PAH, specifically mean pulmonary artery pressure (PAPm) ≥25 mmHg (at rest), pulmonary capillary wedge pressure (PCWP) (or left ventricular end diastolic pressure) ≤15 mmHg, and pulmonary vascular resistance (PVR) >3 mmHg/L/min
  • Within the past 12 months, patients must have had a chest radiograph consistent with the diagnosis of PAH
  • Willing and able to follow all study procedures

Exclusion criteria

Exclusion Criteria:

  • Considering pregnancy, are pregnant and/or lactating
  • PAH due to conditions other than noted in the above inclusion criteria.
  • Have had any change in or discontinued any PAH medication within the last three months, including but not limited to endothelin receptor antagonist (ERA), or calcium channel blockers (CCB) (with the exception of anticoagulants)
  • Have received any prostanoid within the 30 days before screening or are scheduled to receive any during the course of the study
  • Have received any medication within 30 days prior to the start of this study or are scheduled to receive another investigational drug during the course of this study
  • Have a known intolerance to any drug, especially to treprostinil sodium or prostanoids
  • Have an increased risk of hemorrhage
  • Have a new type of chronic therapy (e.g., a different category of vasodilator, diuretic) for PAH added within the last month, except anticoagulants
  • Have any musculoskeletal disease or any other disease that would limit ambulation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
235 participants (actual)

Study arms

  • Experimental
    Inhaled treprostinil

    0.9 mg/mL treprostinil for inhalation supplied in 2.9mL ampoules for use in ultra sonic nebulizer

    Drug: Inhaled treprostinil

  • Placebo comparator
    Placebo

    Placebo inhalation solution for use in ultrasonic nebulizer

    Drug: Placebo inhalation solution

Interventions

  • Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.

    Also known as: Tyvaso

  • DrugPlacebo inhalation solution

    Doses are titrated to 9 breaths four times daily.

    Also known as: Placebo

07

What researchers measure

Primary outcomes

  1. Peak 6-minute Walk Distance

    Change in peak 6-minute walk distance from baseline to Week 12. Peak 6MWD was defined as a 6-minute walk test (6MWT) within 10 to 60 minutes after study drug inhalation

    Time frame: 12 weeks

Secondary outcomes

  1. Clinical Worsening Events

    Clinical worsening was defined as the first incidence of clinical worsening from randomization to the first occurrence of death, transplantation, hospitalization for PAH, or initiation of additional approved PAH therapy.

    Time frame: 12 weeks

  2. Borg Dyspnea Score

    The Borg dyspnea score is a patient reported number between 0 (no perceived shortness of breath) and 10 (maximum perceived shortness of breath), obtained at the completion of each 6MWT.

    Time frame: 12 weeks

  3. New York Heart Association (NYHA) Functional Classification

    Change in NYHA functional class at Week 12. NYHA classifications: Class I - Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II - Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III - Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope. Class IV - Patients with pulmonary hypertension in the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

    Time frame: 12 weeks

  4. Trough 6MWD at Week 12

    Change in 6MWD from Baseline to trough 6MWD at Week 12. Trough was defined as a 6MWT conducted at least 4 hours following study drug inhalation.

    Time frame: 12 Weeks

  5. Peak 6MWD at Week 6

    Change in peak 6MWD between Baseline and Week 6.

    Time frame: 6 weeks

  6. Quality of Life (Minnesota Living With Heart Failure)

    Quality of life as measured by the Minnesota Living With Heart Failure (MLWHF) questionnaire was evaluated at baseline and at Week 12. The MLWHF questionnaire consists of 21 questions assessing how the patient's heart failure has prevented them from living the way they wanted during the defined time period. Each question was graded by the patient with a numeric value between 0 (No/none) and 5 (very much). These scores were then summed across the 21 questions for a Global Score. Global scores ranged from 0 to 105. These questions were further grouped into Physical (8 of the questions) and Emotional (5 of the questions) dimensions to further characterize the effect of heart failure on the patient's life. Physical scores ranged from 0 to 40, and emotional scores ranged from 0 to 25. For all 3 categories, the lower the score, the better the outcome. Values presented as change from Baseline.

    Time frame: 12 weeks

  7. Change in Signs and Symptoms of PAH

    Signs and symptoms of PAH (Loud P2 sound, Ascites, Right ventricular S3 sound, Dyspnea, Right ventricular S4 sound, Orthopnea, Right ventricular heave, Dizziness, Murmur of tricuspid insufficiency, Syncope, Murmur of pulmonic insufficiency, Chest pain, Hepatomegaly, Palpitations, Jugular venous distension at 45 degrees, Fatigue, Edema) were assessed at Baseline and Week 12. The status of each sign and symptom ("absent" or "present") was assessed at each visit. To assess overall change from baseline in signs and symptoms, a "1" was assigned for each sign and symptom that was "present" at the Week 12 but was "absent" at baseline, a "-1" was assigned for each sign and symptom that was "absent" at Week 12 but was "present" at baseline, and a "0" was assigned for no change. An overall change score at each post-baseline assessment was then calculated by summing these values for all signs and symptoms. The overall change score had the potential to range from -17 to 17.

    Time frame: 12 weeks

  8. N-terminal Pro-B-Type Natriuretic Peptide (NT Pro-BNP)

    Change in NT pro-BNP from Baseline to Week 12. Plasma samples were collected from patients at Baseline and Week 12 in order to measure any change over time in circulating plasma levels of this biomarker.

    Time frame: 12 weeks

08

Results

Posted Aug 12, 2013

Participant flow

The first subject was enrolled on 7 June 2005 and the last subject exited the study on 12 Oct 2007.

Participant flow — Overall Study
MilestoneInhaled TreprostinilPlacebo
Started115120
Completed102110
Not completed1310

Outcome measures

PrimaryPeak 6-minute Walk Distance

Change in peak 6-minute walk distance from baseline to Week 12. Peak 6MWD was defined as a 6-minute walk test (6MWT) within 10 to 60 minutes after study drug inhalation

Time frame:
12 weeks
Reported as:
Median · meters
Peak 6-minute Walk Distance
metersInhaled TreprostinilPlacebo
Week 12366.0 (300.0 to 423.0)360.0 (296.0 to 414.9)
Change from Baseline21.6 (-8.0 to 54.0)3.0 (-26.0 to 31.5)
Statistical analysis
  • Inhaled Treprostinil vs Placebo · ANCOVA · p = 0.00044 · Hodges-lehmann estimate: 20.0 · 95% CI 8.0 to 32.8Lowest rank was assigned for death, discontinuation due to disease progression, and for patients who initiated additional approved PAH therapy.
SecondaryClinical Worsening Events

Clinical worsening was defined as the first incidence of clinical worsening from randomization to the first occurrence of death, transplantation, hospitalization for PAH, or initiation of additional approved PAH therapy.

Time frame:
12 weeks
Reported as:
Number · clinical worsening events
Clinical Worsening Events
clinical worsening eventsInhaled TreprostinilPlacebo
Clinical Worsening Events46
SecondaryBorg Dyspnea Score

The Borg dyspnea score is a patient reported number between 0 (no perceived shortness of breath) and 10 (maximum perceived shortness of breath), obtained at the completion of each 6MWT.

Time frame:
12 weeks
Reported as:
Mean · score
Borg Dyspnea Score
scoreInhaled TreprostinilPlacebo
Week 123.68 ± 2.263.91 ± 2.33
Change from Baseline0.0 ± 2.070.0 ± 1.72
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Wilcoxon rank sum test · p = 0.623 · Hodges-lehmann (h-l): 0.0 · 95% CI -0.5 to 0.0
SecondaryNew York Heart Association (NYHA) Functional Classification

Change in NYHA functional class at Week 12. NYHA classifications: Class I - Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II - Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III - Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope. Class IV - Patients with pulmonary hypertension in the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

Time frame:
12 weeks
Reported as:
Number · participants
New York Heart Association (NYHA) Functional Classification
participantsInhaled TreprostinilPlacebo
NYHA Class II22 (0 to 0)22
NYHA Class III8893
NYHA Class IV55
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Wilcoxon rank sum test · p = 0.807 (Imputation strategies were implemented for 16 inhaled treprostinil subjects and 9 placebo subjects without values reported at Week 12) · Hodges-lehmann (h-l): 0.0 · 95% CI 0.0 to 0.0
SecondaryTrough 6MWD at Week 12

Change in 6MWD from Baseline to trough 6MWD at Week 12. Trough was defined as a 6MWT conducted at least 4 hours following study drug inhalation.

Time frame:
12 Weeks
Reported as:
Median · meters
Trough 6MWD at Week 12
metersInhaled TreprostinilPlacebo
Week 12 trough364.0 (313.0 to 420.0)365.0 (289.0 to 422.0)
Change from Baseline12.4 (-10.0 to 51.3)0.8 (-17.9 to 25.0)
Statistical analysis
  • Inhaled Treprostinil vs Placebo · ANCOVA · p = 0.007 · Hodges-lehmann (h-l): 13.7 · 95% CI 4.0 to 24.8
SecondaryPeak 6MWD at Week 6

Change in peak 6MWD between Baseline and Week 6.

Time frame:
6 weeks
Reported as:
Median · meters
Peak 6MWD at Week 6
metersInhaled TreprostinilPlacebo
Week 6 Values375 (305 to 421)367 (292 to 419)
Change from Baseline21.6 (-4.0 to 51.8)3.0 (-16.5 to 22.0)
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Wilcoxon rank sum test · p = 0.0003 · Hodges-lehmann (h-l): 18.5 · 95% CI 8.5 to 28.3
SecondaryQuality of Life (Minnesota Living With Heart Failure)

Quality of life as measured by the Minnesota Living With Heart Failure (MLWHF) questionnaire was evaluated at baseline and at Week 12. The MLWHF questionnaire consists of 21 questions assessing how the patient's heart failure has prevented them from living the way they wanted during the defined time period. Each question was graded by the patient with a numeric value between 0 (No/none) and 5 (very much). These scores were then summed across the 21 questions for a Global Score. Global scores ranged from 0 to 105. These questions were further grouped into Physical (8 of the questions) and Emotional (5 of the questions) dimensions to further characterize the effect of heart failure on the patient's life. Physical scores ranged from 0 to 40, and emotional scores ranged from 0 to 25. For all 3 categories, the lower the score, the better the outcome. Values presented as change from Baseline.

Time frame:
12 weeks
Reported as:
Median · units on a scale
Quality of Life (Minnesota Living With Heart Failure)
units on a scaleInhaled TreprostinilPlacebo
Global Score-3.0 ± 18.70.0 ± 16.2
Physical Dimension-1.4 ± 8.90.0 ± 7.1
Emotional Dimension0.0 ± 5.70.0 ± 5.7
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Wilcoxon rank sum test · p = 0.027 · Hodges-lehman estimate: -4.0 · 95% CI -8.0 to 0
  • Inhaled Treprostinil vs Placebo · Wilcoxon rank sum test · p = 0.037 · Hodges-lehman estimate: -2.0 · 95% CI -3.0 to 0.0
  • Inhaled Treprostinil vs Placebo · Wilcoxon rank sum test · p = 0.173 · Hodges-lehman estimate: -1.0 · 95% CI -2.0 to 0.0
SecondaryChange in Signs and Symptoms of PAH

Signs and symptoms of PAH (Loud P2 sound, Ascites, Right ventricular S3 sound, Dyspnea, Right ventricular S4 sound, Orthopnea, Right ventricular heave, Dizziness, Murmur of tricuspid insufficiency, Syncope, Murmur of pulmonic insufficiency, Chest pain, Hepatomegaly, Palpitations, Jugular venous distension at 45 degrees, Fatigue, Edema) were assessed at Baseline and Week 12. The status of each sign and symptom ("absent" or "present") was assessed at each visit. To assess overall change from baseline in signs and symptoms, a "1" was assigned for each sign and symptom that was "present" at the Week 12 but was "absent" at baseline, a "-1" was assigned for each sign and symptom that was "absent" at Week 12 but was "present" at baseline, and a "0" was assigned for no change. An overall change score at each post-baseline assessment was then calculated by summing these values for all signs and symptoms. The overall change score had the potential to range from -17 to 17.

Time frame:
12 weeks
Reported as:
Median · units on a scale
Change in Signs and Symptoms of PAH
units on a scaleInhaled TreprostinilPlacebo
Change in Signs and Symptoms of PAH0 ± 3.50 ± 2.5
SecondaryN-terminal Pro-B-Type Natriuretic Peptide (NT Pro-BNP)

Change in NT pro-BNP from Baseline to Week 12. Plasma samples were collected from patients at Baseline and Week 12 in order to measure any change over time in circulating plasma levels of this biomarker.

Time frame:
12 weeks
Reported as:
Median · pg/mL
N-terminal Pro-B-Type Natriuretic Peptide (NT Pro-BNP)
pg/mLInhaled TreprostinilPlacebo
Week 12377 (124 to 1091)756 (177 to 2213)
Change from Baseline-57 (-396 to 34)40 (-93 to 288)
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Wilcoxon rank sum test · p = 0.001 · Hodges-lehman estimate: -167 · 95% CI -333 to -64

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Treprostinil—9/115 (7.8%)101/115 (87.8%)
Placebo—13/120 (10.8%)100/120 (83.3%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventInhaled TreprostinilPlacebo
Worsening PAHRespiratory, thoracic and mediastinal disorders3/1152/120
SyncopeNervous system disorders2/1151/120
AnemiaBlood and lymphatic system disorders1/1150/120
Abdominal painGastrointestinal disorders1/1150/120
Diabetes mellitusEndocrine disorders1/1150/120
DiarrheaGastrointestinal disorders1/1150/120
Gastric ulcerGastrointestinal disorders1/1150/120
right ventricular failureCardiac disorders1/1150/120
AnxietyNervous system disorders0/1151/120
Atrial flutterCardiac disorders0/1151/120
Most frequent other events
Showing 10 of 17
Most frequent other events
EventInhaled TreprostinilPlacebo
coughRespiratory, thoracic and mediastinal disorders62/11535/120
headacheNervous system disorders47/11527/120
nauseaGastrointestinal disorders22/11513/120
dizzinessNervous system disorders20/11518/120
flushingVascular disorders17/1151/120
throat irritationRespiratory, thoracic and mediastinal disorders16/11510/120
Upper respiratory tract infectionInfections and infestations10/11514/120
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders13/1157/120
fatigueGeneral disorders10/11512/120
diarrheaGastrointestinal disorders11/1159/120

Baseline characteristics

Age, Continuous
Age, Continuous(years)Inhaled TreprostinilPlaceboTotal
Mean55 ± 13.152 (18 to 75)54 (18 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Inhaled TreprostinilPlaceboTotal
Female9398191
Male222244
Pulmonary Arterial Hypertension (PAH) Etiology
Pulmonary Arterial Hypertension (PAH) Etiology(participants)Inhaled TreprostinilPlaceboTotal
Idiopathic PAH (IPAH)6467131
Connective Tissue Disease (CTD)403777
Other111627
Background PAH Therapy
Background PAH Therapy(participants)Inhaled TreprostinilPlaceboTotal
Bosentan7788165
Sildenafil383270
Time on Background Therapy
Time on Background Therapy(weeks)Inhaled TreprostinilPlaceboTotal
Bosentan98 ± 7990 ± 7594 ± 77
Sildenafil65 ± 6077 ± 6970 ± 64
Baseline NYHA Class
Baseline NYHA Class(participants)Inhaled TreprostinilPlaceboTotal
Class III112118230
Class IV325
Baseline Six-Minute Walk Distance (6MWD)
Baseline Six-Minute Walk Distance (6MWD)(meters)Inhaled TreprostinilPlaceboTotal
Mean346 ± 63351 ± 69348 ± 66
09

Study locations

30 sites
  • University of Alabama
    Birmingham, Alabama 35294-0006, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • UCSD Medical center
    La Jolla, California 92037, United States
  • UCLA Medical Center
    Torrance, California 90502, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Orlando Heart Center
    Orlando, Florida 32806, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • University of Michigan
    Ann Arbor, Michigan 48109-5853, United States
  • Bethe Israel Medical Center
    New York, New York 10003, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-2650, United States
  • UTSW Medical Center
    Dallas, Texas 75235, United States
  • Universitatsklinikfur Innere Medizin II
    Wein, Vienna 1090, Austria
  • Medical University Graz
    Graz, Austria
  • Universite Libre de Bruxelles
    Brussels, 1070, Belgium
  • University Hospital Gasthuisburg
    Leuven, Belgium
  • Hospital Antoine Beclere
    Paris, 92141, France
  • Univesitatsklinikum Giessen und Marburg GmbH
    Geissen, D-35392, Germany
  • Pulmonary Hypertension Unit
    Dublin 7, Ireland
  • Rambam Medical Center
    Haifa, 31096, Israel
  • The Pulmonary Institute
    Jerusalem 91120, Israel
  • The Pulmonary Institute
    Petach Tikvah 49100, Israel
  • Instituto Malattie dell'Apparato Vascolare
    Bologna, Italy
  • University of Barcelona
    Barcelona, 08036, Spain
  • Papworth Hospital
    Cambridge, CB3 8RE, United Kingdom
  • Scottish Pulmonary Vascular Unit
    Glasgow GII 6NT, United Kingdom
  • Royal Fee Hospital
    London, United Kingdom
10

References and documents

Publications

  • McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010 May 4;55(18):1915-22. doi: 10.1016/j.jacc.2010.01.027. PubMed 20430262 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 5 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2005
First posted
Sep 7, 2005
Start
Jun 2005
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Results first posted
Aug 12, 2013
Last update
Jan 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00147199
Responsible party
Sponsor
First posted
Sep 7, 2005
Start date
Jun 2005
Primary completion
Oct 2007
Completion
Oct 2007
Results posted
Aug 12, 2013
Last update
Jan 2, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion